Chicago: Lilly’s Antibody Appears to Do No Harm, But Will It Help?
It’s instructive to learn how pharmaceutical companies are navigating the transition for new experimental AD drugs from Phase 2 to 3...
6389 RESULTS
Sort By:
It’s instructive to learn how pharmaceutical companies are navigating the transition for new experimental AD drugs from Phase 2 to 3...
A paper suggests that a non-invasive imaging procedure detects buildup of amyloid-β...
The story of how Elan/Wyeth’s antibody therapy fared at the ICAD is one of the stranger tales in AD drug development...
An oral antihistamine has emerged in the race to become the first AD drug with stronger, more lasting benefit than any of the drugs currently available...
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
Companies have dealt with the uncertainty created by the Phase 2 problem in clinical trial design in several ways...
On the last day of ICAD, recent disappointing AD trial results were put into a broader perspective...
On 31 July, the 11th International Conference on AD drew to a close...
The true prevalence of dementia in developing nations may be higher than is widely believed...
This season might go down in the Alzheimer research history as the summer of calcium...
As with many neurodegenerative diseases, predicting survival time in patients with ALS is a tricky business...
Are oddly behaving placebo groups scuppering clinical trials, or are potential treatments simply not living up to expectation?...
In Alzheimer disease clinical trials, placebo groups seem to be worsening at a more leisurely rate than they once did...
A trio of collaborators has unearthed an unlikely regulator of α-synuclein gene (SNCA) expression...
People affected by early-onset familial forms (eFAD) often wonder how discoveries apply to them...